Published in Liver Int on March 12, 2010
Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care (2012) 3.11
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33
NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol (2013) 2.20
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10
Obesity, inflammation, and liver cancer. J Hepatol (2011) 2.09
Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) (2012) 1.90
Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist (2012) 1.79
Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology (2014) 1.75
Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care (2014) 1.68
Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care (2011) 1.52
The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int (2014) 1.29
Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therap Adv Gastroenterol (2016) 1.09
Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One (2013) 1.06
The mTOR pathway in hepatic malignancies. Hepatology (2013) 1.02
Metabolic roles of AMPK and metformin in cancer cells. Mol Cells (2013) 1.02
Cancer risk in HBV patients with statin and metformin use: a population-based cohort study. Medicine (Baltimore) (2015) 1.02
Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol (2013) 1.00
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma. Oncologist (2012) 0.97
AMP-Activated Protein Kinase α 2 Isoform Suppression in Primary Breast Cancer Alters AMPK Growth Control and Apoptotic Signaling. Genes Cancer (2013) 0.94
Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne) (2015) 0.89
Insulin resistance and chronic liver disease. World J Hepatol (2011) 0.88
Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci (2013) 0.88
Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol (2015) 0.85
Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways. World J Hepatol (2015) 0.85
Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol (2015) 0.84
Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats. Saudi Pharm J (2012) 0.83
Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy. Dig Dis Sci (2016) 0.83
Metformin and metabolic diseases: a focus on hepatic aspects. Front Med (2015) 0.83
Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes. Br J Cancer (2014) 0.83
Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PLoS One (2012) 0.82
Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World J Hepatol (2014) 0.82
Diabetes mellitus and metformin in hepatocellular carcinoma. World J Gastroenterol (2016) 0.82
Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention. J Clin Transl Hepatol (2013) 0.81
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. J Hematol Oncol (2016) 0.81
Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol (2016) 0.81
Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. Cancer (2016) 0.80
Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol (2014) 0.80
Metformin does not improve survival in patients with hepatocellular carcinoma. World J Gastroenterol (2014) 0.80
Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin. World J Hepatol (2015) 0.80
Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk. Gastroenterol Res Pract (2015) 0.79
Systematic review: Preventive and therapeutic applications of metformin in liver disease. World J Hepatol (2015) 0.79
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. Cancer Sci (2016) 0.78
Metformin and cancer. Rev Diabet Stud (2014) 0.78
Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects. World J Gastroenterol (2016) 0.77
Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. Oncotarget (2016) 0.77
Metformin Prevents Renal Fibrosis in Mice with Unilateral Ureteral Obstruction and Inhibits Ang II-Induced ECM Production in Renal Fibroblasts. Int J Mol Sci (2016) 0.77
Modulation of Autophagy by Sorafenib: Effects on Treatment Response. Front Pharmacol (2016) 0.77
Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma. Sci Rep (2016) 0.76
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine (Baltimore) (2017) 0.75
A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma. J Hepatocell Carcinoma (2015) 0.75
Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China. Medicine (Baltimore) (2017) 0.75
Clinical outcomes of patients with and without diabetes mellitus after hepatectomy: A systematic review and meta-analysis. PLoS One (2017) 0.75
Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway. Oncotarget (2017) 0.75
Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs. Pharmaceuticals (Basel) (2016) 0.75
Metformin exhibits the anti-proliferation and anti-invasion effects in hepatocellular carcinoma cells after insufficient radiofrequency ablation. Cancer Cell Int (2017) 0.75
Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. Oncotarget (2016) 0.75
Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Ann Transl Med (2017) 0.75
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma. Dig Dis Sci (2017) 0.75
KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum Mutat (2005) 1.47
Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev (2006) 1.47
Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol (2009) 1.33
Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin. World J Gastroenterol (2008) 1.12
Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer (2007) 1.12
Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol (2010) 1.02
Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and Type 2 diabetes mellitus. Expert Rev Gastroenterol Hepatol (2009) 0.86
Alcohol and HCV chronic infection are risk cofactors of type 2 diabetes mellitus for hepatocellular carcinoma in Italy. Int J Environ Res Public Health (2010) 0.82
Anti-zinc transporter protein 8 autoantibodies significantly improve the diagnostic approach to type 1 diabetes: an Italian multicentre study on paediatric patients. Auto Immun Highlights (2015) 0.75
Type 2 diabetes mellitus and increased prevalence of hepatocarcinoma in HIV-infected population. J Acquir Immune Defic Syndr (2008) 0.75